OnabotulinumtoxinA · powder for injection
Misc., Injections & Implants
Approved uses
Blepharospasm associated with dystonia, age 12 and over
1.25 to 2.5 Units injected into each of 3 sites per affected eye
Watch for exposure keratopathy afterwards: reduced blinking is the mechanism, not a coincidence
Strabismus, age 12 and over
Dose selected from the prism diopter correction required, or from the previous response to treatment
Contraindications
- Hypersensitivity to any botulinum toxin product or to any component of the formulation
- Infection at the proposed injection site
- Intradetrusor injection in a patient with a urinary tract infection, or with urinary retention or a post-void residual urine volume above 200 mL who is not routinely performing clean intermittent self-catheterization
100 Unit and 200 Unit single-dose vials, vacuum-dried powder for reconstitution
BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or autonomic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, BOTOX produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extrajunctional acetylcholine receptors may develop.
Warnings & Precautions
- Distant spread of toxin effect: effects may spread from the area of injection; symptoms may include generalized muscle weakness, diplopia, ptosis, dysphagia and breathing difficulties, and have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. Risk is probably greatest in children treated for spasticity. This carries a boxed warning. Seek immediate medical care if swallowing, speech or respiratory disorders occur.
- Lack of interchangeability between botulinum toxin products: potency Units of BOTOX are not interchangeable with other preparations and cannot be compared to nor converted into units of any other botulinum toxin product.
- Serious adverse reactions with unapproved use: serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, some with fatal outcomes, have been reported with injections for unapproved uses. These were not necessarily related to distant spread of toxin. The safety and effectiveness of BOTOX for unapproved uses have not been established.
- Hypersensitivity reactions: serious and/or immediate hypersensitivity reactions, including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea, have been reported. If such a reaction occurs, discontinue further injection and immediately institute appropriate medical therapy.
- Increased risk of clinically significant effects: monitor patients with peripheral motor neuropathic disease, amyotrophic lateral sclerosis, or neuromuscular junction disorders such as myasthenia gravis or Lambert-Eaton syndrome. Known or unrecognized disease may raise the risk of generalized weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise at therapeutic doses.
- Dysphagia: treatment can result in swallowing or breathing difficulties, and patients with pre-existing swallowing or breathing difficulties may be more susceptible. Deaths as a complication of severe dysphagia have been reported, and dysphagia may persist for several months.
- Loss of breathing capacity: weakened neck muscles that serve as accessory muscles of ventilation may cause a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles, and respiratory failure has been reported.
- Pulmonary effects in compromised respiratory status: patients with compromised respiratory status treated for spasticity should be monitored closely.
- Forced vital capacity decrease: the event rate of at least a 15% or 20% decrease in forced vital capacity (FVC) was generally greater with BOTOX than placebo in adults with stable reduced pulmonary function treated for upper limb spasticity (differences were not statistically significant) and in adults with restrictive lung disease of neuromuscular etiology treated for detrusor overactivity associated with a neurologic condition.
- Corneal exposure and ulceration: reduced blinking from injection of the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders. Treat any epithelial defect vigorously, which may require protective drops, ointment, therapeutic soft contact lenses, or closure of the eye by patching or other means.
- Retrobulbar hemorrhages: during administration for strabismus, retrobulbar hemorrhages sufficient to compromise retinal circulation have occurred. Appropriate instruments to decompress the orbit should be accessible.
- Ecchymosis and ptosis: ecchymosis occurs easily in the soft eyelid tissues and can be prevented by applying pressure at the injection site immediately after the injection. Avoiding injection near the levator palpebrae superioris may reduce the complication of ptosis.
- Bronchitis and upper respiratory tract infections: bronchitis was reported more frequently with BOTOX than placebo in adults treated for upper limb spasticity. Upper respiratory tract infections were reported more frequently with BOTOX than placebo in adults with reduced lung function treated for upper limb spasticity, in adults treated for lower limb spasticity, and in pediatric patients treated for upper limb spasticity.
- Autonomic dysreflexia: could occur with intradetrusor injections in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy.
- Urinary tract infections: BOTOX increases the incidence of urinary tract infection. In overactive bladder patients with more than 2 UTIs in the past 6 months, chronic antibiotics for recurrent UTIs, or multiple recurrent UTIs during treatment, consider use only when the benefit is likely to outweigh the potential risk.
- Urinary retention: treat only patients willing and able to initiate catheterization post-treatment, if required. In patients who are not catheterizing, assess post-void residual (PVR) urine volume within 2 weeks post-treatment and periodically as medically appropriate up to 12 weeks, particularly with multiple sclerosis or diabetes mellitus. Depending on symptoms, institute catheterization if PVR urine volume exceeds 200 mL and continue until PVR falls below 200 mL.
- Human albumin and transmission of viral diseases: the product contains albumin, a derivative of human blood, and carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). No cases of transmission have ever been identified for licensed albumin.
Common Side Effects
In blepharospasm, the most frequently reported adverse reactions were ptosis (21%), superficial punctate keratitis (6%) and eye dryness (6%). In strabismus, extraocular muscles adjacent to the injection site can be affected, causing vertical deviation, especially with higher doses; this occurred in 17% of adults treated for horizontal strabismus. The incidence of ptosis has been reported to depend on the muscle injected (1% after inferior rectus, 16% after horizontal rectus and 38% after superior rectus injections). In cervical dystonia, the most frequently reported adverse reactions were dysphagia (19%), upper respiratory infection (12%), neck pain (11%) and headache (11%). Other indications have their own common reactions, such as urinary tract infection after bladder injection and neck pain and headache in chronic migraine.
Pregnancy: No studies or adequate data from postmarketing surveillance on the developmental risk in pregnant women. Based on animal data, may cause fetal harm; animal studies showed decreased fetal weight and skeletal ossification at clinically relevant doses, associated with maternal toxicity.
Lactation: No data on the presence of BOTOX in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Consider the benefits of breastfeeding along with the mother's clinical need for BOTOX and any potential adverse effects on the breastfed infant.
Blepharospasm and strabismus: safety and effectiveness in pediatric patients below the age of 12 years have not been established. Established for detrusor overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication, and for spasticity in pediatric patients 2 to 17 years of age. Not established for overactive bladder in pediatric patients, for chronic migraine or axillary hyperhidrosis below 18 years, or for cervical dystonia below 16 years.